Drugs / BAY1125976
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01915576 | Sep 2013 → Jul 2016 | neoplasm | Bayer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY1125976 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01915576 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase AKT2 inhibitor” CHEMBL4751394 ↗2“Serine/threonine-protein kinase AKT inhibitor” CHEMBL4751394 ↗ “Allosteric AKT 1/2 Inhibitor” NCT01915576 ↗ |
| Modality | Small molecule | — CHEMBL4751394 ↗ |
| Route | Oral | “BAY1125976 will be given daily as single oral application.” NCT01915576 ↗ |
| Target | AKT1 | “Serine/threonine-protein kinase AKT inhibitor” CHEMBL4751394 ↗ |
| Target | AKT2 | “Serine/threonine-protein kinase AKT2 inhibitor” CHEMBL4751394 ↗ |